Our News Bureau – Mumbai
Strides Arcolab has received approval from the US FDA for Vancomycin Hydrochloride Capsules USP, 125 mg and 250 mg. According to IMS health data, Vancomycin Capsules had total US sales of $ 332 million for the twelve months ending February 2012, with no prior generic approvals.
Arun Kumar, Group Chief Executive Officer of Strides stated, “Oral Vancomycin development is one among the many value generics programmes being undertaken at the Strides Group with a special focus to develop niche and difficult to manufacture products.”
The product will be launched immediately through Alvogen on a profit share basis.
- Advertisement -
